Elekta AB (publ)
Elekta AB (publ) (EKTAF) Stock Competitors & Peer Comparison
See (EKTAF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EKTAF | $6.06 | +1.00% | 2.2B | -606.00 | -$0.01 | +4.27% |
| SRTOY | $19.46 | +2.76% | 189.7B | 60.94 | $0.32 | +0.41% |
| ESLOY | $107.07 | +4.21% | 97.6B | 36.50 | $2.91 | +2.13% |
| ESLOF | $209.53 | +5.43% | 95.4B | 35.33 | $5.83 | +2.28% |
| SOAGY | $52.79 | -0.03% | 77.6B | 96.55 | $0.55 | +0.32% |
| HOCPF | $190.15 | +7.31% | 63.8B | 40.81 | $4.66 | +1.01% |
| HOCPY | $174.97 | -2.37% | 62B | 39.67 | $4.66 | +0.93% |
| RSMDF | $24.89 | +0.00% | 36.3B | 23.93 | $1.04 | +1.11% |
| MECNY | $88.63 | +0.00% | 26.9B | N/A | N/A | N/A |
| TRUMF | $13.45 | +1.89% | 19.8B | 24.45 | $0.55 | +1.46% |
Stock Comparison
EKTAF vs SRTOY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SRTOY has a market cap of 189.7B. Regarding current trading prices, EKTAF is priced at $6.06, while SRTOY trades at $19.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SRTOY's P/E ratio is 60.94. In terms of profitability, EKTAF's ROE is -0.00%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SRTOY's competition here
EKTAF vs ESLOY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ESLOY has a market cap of 97.6B. Regarding current trading prices, EKTAF is priced at $6.06, while ESLOY trades at $107.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ESLOY's P/E ratio is 36.50. In terms of profitability, EKTAF's ROE is -0.00%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to ESLOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ESLOY's competition here
EKTAF vs ESLOF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ESLOF has a market cap of 95.4B. Regarding current trading prices, EKTAF is priced at $6.06, while ESLOF trades at $209.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ESLOF's P/E ratio is 35.33. In terms of profitability, EKTAF's ROE is -0.00%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ESLOF's competition here
EKTAF vs SOAGY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SOAGY has a market cap of 77.6B. Regarding current trading prices, EKTAF is priced at $6.06, while SOAGY trades at $52.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SOAGY's P/E ratio is 96.55. In terms of profitability, EKTAF's ROE is -0.00%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SOAGY's competition here
EKTAF vs HOCPF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, HOCPF has a market cap of 63.8B. Regarding current trading prices, EKTAF is priced at $6.06, while HOCPF trades at $190.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas HOCPF's P/E ratio is 40.81. In terms of profitability, EKTAF's ROE is -0.00%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, EKTAF and HOCPF have similar daily volatility (0.00).Check HOCPF's competition here
EKTAF vs HOCPY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, HOCPY has a market cap of 62B. Regarding current trading prices, EKTAF is priced at $6.06, while HOCPY trades at $174.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas HOCPY's P/E ratio is 39.67. In terms of profitability, EKTAF's ROE is -0.00%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, EKTAF is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check HOCPY's competition here
EKTAF vs RSMDF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, RSMDF has a market cap of 36.3B. Regarding current trading prices, EKTAF is priced at $6.06, while RSMDF trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas RSMDF's P/E ratio is 23.93. In terms of profitability, EKTAF's ROE is -0.00%, compared to RSMDF's ROE of +0.24%. Regarding short-term risk, EKTAF is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check RSMDF's competition here
EKTAF vs MECNY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, MECNY has a market cap of 26.9B. Regarding current trading prices, EKTAF is priced at $6.06, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas MECNY's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, EKTAF and MECNY have similar daily volatility (0.00).Check MECNY's competition here
EKTAF vs TRUMF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TRUMF has a market cap of 19.8B. Regarding current trading prices, EKTAF is priced at $6.06, while TRUMF trades at $13.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TRUMF's P/E ratio is 24.45. In terms of profitability, EKTAF's ROE is -0.00%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, EKTAF and TRUMF have similar daily volatility (0.00).Check TRUMF's competition here
EKTAF vs TRUMY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TRUMY has a market cap of 19B. Regarding current trading prices, EKTAF is priced at $6.06, while TRUMY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TRUMY's P/E ratio is 22.98. In terms of profitability, EKTAF's ROE is -0.00%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TRUMY's competition here
EKTAF vs SDMHF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SDMHF has a market cap of 18.5B. Regarding current trading prices, EKTAF is priced at $6.06, while SDMHF trades at $196.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SDMHF's P/E ratio is 58.64. In terms of profitability, EKTAF's ROE is -0.00%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to SDMHF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SDMHF's competition here
EKTAF vs SAUHY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SAUHY has a market cap of 18B. Regarding current trading prices, EKTAF is priced at $6.06, while SAUHY trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SAUHY's P/E ratio is 40.32. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, EKTAF is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SAUHY's competition here
EKTAF vs SAUHF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SAUHF has a market cap of 17.5B. Regarding current trading prices, EKTAF is priced at $6.06, while SAUHF trades at $109.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SAUHF's P/E ratio is 38.41. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, EKTAF is less volatile compared to SAUHF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SAUHF's competition here
EKTAF vs SUVPF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SUVPF has a market cap of 17.3B. Regarding current trading prices, EKTAF is priced at $6.06, while SUVPF trades at $250.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SUVPF's P/E ratio is 91.24. In terms of profitability, EKTAF's ROE is -0.00%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SUVPF's competition here
EKTAF vs SSSGY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SSSGY has a market cap of 14.9B. Regarding current trading prices, EKTAF is priced at $6.06, while SSSGY trades at $43.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SSSGY's P/E ratio is 78.54. In terms of profitability, EKTAF's ROE is -0.00%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SSSGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SSSGY's competition here
EKTAF vs SARTF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SARTF has a market cap of 14.7B. Regarding current trading prices, EKTAF is priced at $6.06, while SARTF trades at $212.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SARTF's P/E ratio is 76.94. In terms of profitability, EKTAF's ROE is -0.00%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, EKTAF and SARTF have similar daily volatility (0.00).Check SARTF's competition here
EKTAF vs CLPBY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CLPBY has a market cap of 14.4B. Regarding current trading prices, EKTAF is priced at $6.06, while CLPBY trades at $6.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CLPBY's P/E ratio is 22.82. In terms of profitability, EKTAF's ROE is -0.00%, compared to CLPBY's ROE of +0.25%. Regarding short-term risk, EKTAF is less volatile compared to CLPBY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CLPBY's competition here
EKTAF vs FSPKF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, FSPKF has a market cap of 13.5B. Regarding current trading prices, EKTAF is priced at $6.06, while FSPKF trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas FSPKF's P/E ratio is 52.32. In terms of profitability, EKTAF's ROE is -0.00%, compared to FSPKF's ROE of +0.30%. Regarding short-term risk, EKTAF and FSPKF have similar daily volatility (0.00).Check FSPKF's competition here
EKTAF vs CLPBF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CLPBF has a market cap of 13.4B. Regarding current trading prices, EKTAF is priced at $6.06, while CLPBF trades at $64.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CLPBF's P/E ratio is 23.28. In terms of profitability, EKTAF's ROE is -0.00%, compared to CLPBF's ROE of +0.25%. Regarding short-term risk, EKTAF and CLPBF have similar daily volatility (0.00).Check CLPBF's competition here
EKTAF vs OCPNF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, OCPNF has a market cap of 10.4B. Regarding current trading prices, EKTAF is priced at $6.06, while OCPNF trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas OCPNF's P/E ratio is 17.57. In terms of profitability, EKTAF's ROE is -0.00%, compared to OCPNF's ROE of +0.11%. Regarding short-term risk, EKTAF is less volatile compared to OCPNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check OCPNF's competition here
EKTAF vs CNVVF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CNVVF has a market cap of 5.8B. Regarding current trading prices, EKTAF is priced at $6.06, while CNVVF trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CNVVF's P/E ratio is 33.22. In terms of profitability, EKTAF's ROE is -0.00%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, EKTAF is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CNVVF's competition here
EKTAF vs AHICF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, AHICF has a market cap of 5.7B. Regarding current trading prices, EKTAF is priced at $6.06, while AHICF trades at $21.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas AHICF's P/E ratio is 51.48. In terms of profitability, EKTAF's ROE is -0.00%, compared to AHICF's ROE of +0.12%. Regarding short-term risk, EKTAF is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check AHICF's competition here
EKTAF vs CNVVY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CNVVY has a market cap of 5.7B. Regarding current trading prices, EKTAF is priced at $6.06, while CNVVY trades at $11.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CNVVY's P/E ratio is 34.47. In terms of profitability, EKTAF's ROE is -0.00%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, EKTAF is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CNVVY's competition here
EKTAF vs SSMXY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SSMXY has a market cap of 5.3B. Regarding current trading prices, EKTAF is priced at $6.06, while SSMXY trades at $8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SSMXY's P/E ratio is 18.19. In terms of profitability, EKTAF's ROE is -0.00%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to SSMXY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SSMXY's competition here
EKTAF vs SSMXF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SSMXF has a market cap of 5.3B. Regarding current trading prices, EKTAF is priced at $6.06, while SSMXF trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SSMXF's P/E ratio is 17.94. In terms of profitability, EKTAF's ROE is -0.00%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SSMXF's competition here
EKTAF vs ADDLF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, EKTAF is priced at $6.06, while ADDLF trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, EKTAF's ROE is -0.00%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, EKTAF and ADDLF have similar daily volatility (0.00).Check ADDLF's competition here
EKTAF vs YPHDF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, YPHDF has a market cap of 4.8B. Regarding current trading prices, EKTAF is priced at $6.06, while YPHDF trades at $354.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas YPHDF's P/E ratio is 19.73. In terms of profitability, EKTAF's ROE is -0.00%, compared to YPHDF's ROE of +0.27%. Regarding short-term risk, EKTAF is less volatile compared to YPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check YPHDF's competition here
EKTAF vs FLMNF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, FLMNF has a market cap of 4.3B. Regarding current trading prices, EKTAF is priced at $6.06, while FLMNF trades at $50.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas FLMNF's P/E ratio is 19.98. In terms of profitability, EKTAF's ROE is -0.00%, compared to FLMNF's ROE of +0.22%. Regarding short-term risk, EKTAF is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check FLMNF's competition here
EKTAF vs FLMNY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, EKTAF is priced at $6.06, while FLMNY trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas FLMNY's P/E ratio is 19.48. In terms of profitability, EKTAF's ROE is -0.00%, compared to FLMNY's ROE of +0.21%. Regarding short-term risk, EKTAF is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check FLMNY's competition here
EKTAF vs ANSLF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ANSLF has a market cap of 3.2B. Regarding current trading prices, EKTAF is priced at $6.06, while ANSLF trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, EKTAF's ROE is -0.00%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, EKTAF and ANSLF have similar daily volatility (0.00).Check ANSLF's competition here
EKTAF vs ANSLY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ANSLY has a market cap of 3B. Regarding current trading prices, EKTAF is priced at $6.06, while ANSLY trades at $78.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ANSLY's P/E ratio is 22.45. In terms of profitability, EKTAF's ROE is -0.00%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, EKTAF and ANSLY have similar daily volatility (0.00).Check ANSLY's competition here
EKTAF vs CZMWY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CZMWY has a market cap of 2.7B. Regarding current trading prices, EKTAF is priced at $6.06, while CZMWY trades at $30.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CZMWY's P/E ratio is 16.22. In terms of profitability, EKTAF's ROE is -0.00%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to CZMWY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CZMWY's competition here
EKTAF vs CZMWF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CZMWF has a market cap of 2.7B. Regarding current trading prices, EKTAF is priced at $6.06, while CZMWF trades at $30.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CZMWF's P/E ratio is 16.12. In terms of profitability, EKTAF's ROE is -0.00%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CZMWF's competition here
EKTAF vs EKTAY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, EKTAY has a market cap of 2.3B. Regarding current trading prices, EKTAF is priced at $6.06, while EKTAY trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas EKTAY's P/E ratio is -597.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to EKTAY's ROE of -0.00%. Regarding short-term risk, EKTAF is less volatile compared to EKTAY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check EKTAY's competition here
EKTAF vs TCGGY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, EKTAF is priced at $6.06, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, EKTAF's ROE is -0.00%, compared to TCGGY's ROE of -0.09%. Regarding short-term risk, EKTAF is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TCGGY's competition here
EKTAF vs TCHBF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TCHBF has a market cap of 2.2B. Regarding current trading prices, EKTAF is priced at $6.06, while TCHBF trades at $175.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TCHBF's P/E ratio is -15.88. In terms of profitability, EKTAF's ROE is -0.00%, compared to TCHBF's ROE of -0.09%. Regarding short-term risk, EKTAF is less volatile compared to TCHBF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TCHBF's competition here
EKTAF vs SHWGY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SHWGY has a market cap of 2B. Regarding current trading prices, EKTAF is priced at $6.06, while SHWGY trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SHWGY's P/E ratio is 8.75. In terms of profitability, EKTAF's ROE is -0.00%, compared to SHWGY's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to SHWGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SHWGY's competition here
EKTAF vs SHWGF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SHWGF has a market cap of 2B. Regarding current trading prices, EKTAF is priced at $6.06, while SHWGF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SHWGF's P/E ratio is 8.80. In terms of profitability, EKTAF's ROE is -0.00%, compared to SHWGF's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SHWGF's competition here
EKTAF vs NPRRF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, EKTAF is priced at $6.06, while NPRRF trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas NPRRF's P/E ratio is 26.21. In terms of profitability, EKTAF's ROE is -0.00%, compared to NPRRF's ROE of N/A. Regarding short-term risk, EKTAF is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check NPRRF's competition here
EKTAF vs BOEUF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, BOEUF has a market cap of 1.6B. Regarding current trading prices, EKTAF is priced at $6.06, while BOEUF trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas BOEUF's P/E ratio is 81.73. In terms of profitability, EKTAF's ROE is -0.00%, compared to BOEUF's ROE of +0.22%. Regarding short-term risk, EKTAF and BOEUF have similar daily volatility (0.00).Check BOEUF's competition here
EKTAF vs TGLVY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TGLVY has a market cap of 1.2B. Regarding current trading prices, EKTAF is priced at $6.06, while TGLVY trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TGLVY's P/E ratio is 31.05. In terms of profitability, EKTAF's ROE is -0.00%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, EKTAF and TGLVY have similar daily volatility (0.00).Check TGLVY's competition here
EKTAF vs SAFLY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SAFLY has a market cap of 1.2B. Regarding current trading prices, EKTAF is priced at $6.06, while SAFLY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SAFLY's P/E ratio is 14.81. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAFLY's ROE of +0.12%. Regarding short-term risk, EKTAF is less volatile compared to SAFLY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SAFLY's competition here
EKTAF vs BITGF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, EKTAF is priced at $6.06, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas BITGF's P/E ratio is 45.50. In terms of profitability, EKTAF's ROE is -0.00%, compared to BITGF's ROE of +0.04%. Regarding short-term risk, EKTAF is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check BITGF's competition here
EKTAF vs PBHDF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, EKTAF is priced at $6.06, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, EKTAF's ROE is -0.00%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, EKTAF and PBHDF have similar daily volatility (0.00).Check PBHDF's competition here
EKTAF vs TDVXF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TDVXF has a market cap of 936.7M. Regarding current trading prices, EKTAF is priced at $6.06, while TDVXF trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TDVXF's P/E ratio is 49.30. In terms of profitability, EKTAF's ROE is -0.00%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, EKTAF is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TDVXF's competition here
EKTAF vs SAFLF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SAFLF has a market cap of 906.6M. Regarding current trading prices, EKTAF is priced at $6.06, while SAFLF trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SAFLF's P/E ratio is 16.50. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAFLF's ROE of +0.12%. Regarding short-term risk, EKTAF and SAFLF have similar daily volatility (0.00).Check SAFLF's competition here
EKTAF vs KSRBF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, KSRBF has a market cap of 841.7M. Regarding current trading prices, EKTAF is priced at $6.06, while KSRBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, EKTAF's ROE is -0.00%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, EKTAF and KSRBF have similar daily volatility (0.00).Check KSRBF's competition here
EKTAF vs HGYMF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, EKTAF is priced at $6.06, while HGYMF trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, EKTAF's ROE is -0.00%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, EKTAF is less volatile compared to HGYMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check HGYMF's competition here
EKTAF vs GRRMF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, GRRMF has a market cap of 713.3M. Regarding current trading prices, EKTAF is priced at $6.06, while GRRMF trades at $31.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas GRRMF's P/E ratio is 25.81. In terms of profitability, EKTAF's ROE is -0.00%, compared to GRRMF's ROE of +0.02%. Regarding short-term risk, EKTAF and GRRMF have similar daily volatility (0.00).Check GRRMF's competition here
EKTAF vs NNCSF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, NNCSF has a market cap of 706.4M. Regarding current trading prices, EKTAF is priced at $6.06, while NNCSF trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas NNCSF's P/E ratio is 47.28. In terms of profitability, EKTAF's ROE is -0.00%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, EKTAF and NNCSF have similar daily volatility (0.00).Check NNCSF's competition here
EKTAF vs JNDOF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, JNDOF has a market cap of 531.1M. Regarding current trading prices, EKTAF is priced at $6.06, while JNDOF trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, EKTAF's ROE is -0.00%, compared to JNDOF's ROE of +0.27%. Regarding short-term risk, EKTAF and JNDOF have similar daily volatility (0.00).Check JNDOF's competition here
EKTAF vs SPMXF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, EKTAF is priced at $6.06, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to SPMXF's ROE of -0.07%. Regarding short-term risk, EKTAF is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SPMXF's competition here
EKTAF vs CLHLF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, EKTAF is priced at $6.06, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, EKTAF's ROE is -0.00%, compared to CLHLF's ROE of +0.16%. Regarding short-term risk, EKTAF and CLHLF have similar daily volatility (0.00).Check CLHLF's competition here
EKTAF vs GUERF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, EKTAF is priced at $6.06, while GUERF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas GUERF's P/E ratio is 8.19. In terms of profitability, EKTAF's ROE is -0.00%, compared to GUERF's ROE of +0.04%. Regarding short-term risk, EKTAF and GUERF have similar daily volatility (0.00).Check GUERF's competition here
EKTAF vs TSNLF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TSNLF has a market cap of 265.1M. Regarding current trading prices, EKTAF is priced at $6.06, while TSNLF trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TSNLF's P/E ratio is 25.14. In terms of profitability, EKTAF's ROE is -0.00%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, EKTAF is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TSNLF's competition here
EKTAF vs OPSSF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, EKTAF is priced at $6.06, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, EKTAF's ROE is -0.00%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, EKTAF is less volatile compared to OPSSF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check OPSSF's competition here
EKTAF vs EEOIF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, EKTAF is priced at $6.06, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, EKTAF's ROE is -0.00%, compared to EEOIF's ROE of N/A. Regarding short-term risk, EKTAF and EEOIF have similar daily volatility (0.00).Check EEOIF's competition here
EKTAF vs OTCFF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, OTCFF has a market cap of 21.4M. Regarding current trading prices, EKTAF is priced at $6.06, while OTCFF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas OTCFF's P/E ratio is -13.33. In terms of profitability, EKTAF's ROE is -0.00%, compared to OTCFF's ROE of +1.38%. Regarding short-term risk, EKTAF and OTCFF have similar daily volatility (0.00).Check OTCFF's competition here
EKTAF vs UEEC Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, UEEC has a market cap of 18.1M. Regarding current trading prices, EKTAF is priced at $6.06, while UEEC trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas UEEC's P/E ratio is -7.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to UEEC's ROE of +0.81%. Regarding short-term risk, EKTAF is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check UEEC's competition here
EKTAF vs TUTH Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TUTH has a market cap of 5.5M. Regarding current trading prices, EKTAF is priced at $6.06, while TUTH trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TUTH's P/E ratio is -2.18. In terms of profitability, EKTAF's ROE is -0.00%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, EKTAF is less volatile compared to TUTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TUTH's competition here
EKTAF vs BLMHF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, EKTAF is priced at $6.06, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, EKTAF's ROE is -0.00%, compared to BLMHF's ROE of N/A. Regarding short-term risk, EKTAF and BLMHF have similar daily volatility (0.00).Check BLMHF's competition here
EKTAF vs PXMVF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, EKTAF is priced at $6.06, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, EKTAF's ROE is -0.00%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, EKTAF is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check PXMVF's competition here
EKTAF vs CBSC Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, EKTAF is priced at $6.06, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CBSC's P/E ratio is -4.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to CBSC's ROE of +0.58%. Regarding short-term risk, EKTAF and CBSC have similar daily volatility (0.00).Check CBSC's competition here
EKTAF vs MCDA Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, EKTAF is priced at $6.06, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas MCDA's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MCDA's ROE of N/A. Regarding short-term risk, EKTAF and MCDA have similar daily volatility (0.00).Check MCDA's competition here
EKTAF vs GVDI Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, GVDI has a market cap of 4.2M. Regarding current trading prices, EKTAF is priced at $6.06, while GVDI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas GVDI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, EKTAF and GVDI have similar daily volatility (0.00).Check GVDI's competition here
EKTAF vs RSCF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, RSCF has a market cap of 3.6M. Regarding current trading prices, EKTAF is priced at $6.06, while RSCF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas RSCF's P/E ratio is -4.20. In terms of profitability, EKTAF's ROE is -0.00%, compared to RSCF's ROE of +0.10%. Regarding short-term risk, EKTAF is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check RSCF's competition here
EKTAF vs NSTGQ Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, EKTAF is priced at $6.06, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, EKTAF is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check NSTGQ's competition here
EKTAF vs ECIA Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ECIA has a market cap of 2.5M. Regarding current trading prices, EKTAF is priced at $6.06, while ECIA trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ECIA's P/E ratio is -6.67. In terms of profitability, EKTAF's ROE is -0.00%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, EKTAF is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ECIA's competition here
EKTAF vs YBGJ Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, YBGJ has a market cap of 1M. Regarding current trading prices, EKTAF is priced at $6.06, while YBGJ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas YBGJ's P/E ratio is -0.84. In terms of profitability, EKTAF's ROE is -0.00%, compared to YBGJ's ROE of +0.38%. Regarding short-term risk, EKTAF and YBGJ have similar daily volatility (0.00).Check YBGJ's competition here
EKTAF vs OJSY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, EKTAF is priced at $6.06, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas OJSY's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to OJSY's ROE of N/A. Regarding short-term risk, EKTAF and OJSY have similar daily volatility (0.00).Check OJSY's competition here
EKTAF vs PDMI Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, EKTAF is priced at $6.06, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas PDMI's P/E ratio is -0.01. In terms of profitability, EKTAF's ROE is -0.00%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, EKTAF and PDMI have similar daily volatility (0.00).Check PDMI's competition here
EKTAF vs WHSI Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, EKTAF is priced at $6.06, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas WHSI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, EKTAF and WHSI have similar daily volatility (0.00).Check WHSI's competition here
EKTAF vs BLFE Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, EKTAF is priced at $6.06, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas BLFE's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, EKTAF and BLFE have similar daily volatility (0.00).Check BLFE's competition here
EKTAF vs QTXB Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, EKTAF is priced at $6.06, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas QTXB's P/E ratio is -0.05. In terms of profitability, EKTAF's ROE is -0.00%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, EKTAF is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check QTXB's competition here
EKTAF vs CEOS Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, CEOS has a market cap of 107.7K. Regarding current trading prices, EKTAF is priced at $6.06, while CEOS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas CEOS's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to CEOS's ROE of +7.33%. Regarding short-term risk, EKTAF and CEOS have similar daily volatility (0.00).Check CEOS's competition here
EKTAF vs IMTH Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, IMTH has a market cap of 101.7K. Regarding current trading prices, EKTAF is priced at $6.06, while IMTH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas IMTH's P/E ratio is -0.03. In terms of profitability, EKTAF's ROE is -0.00%, compared to IMTH's ROE of -0.60%. Regarding short-term risk, EKTAF is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check IMTH's competition here
EKTAF vs LANZ Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, LANZ has a market cap of 74.5K. Regarding current trading prices, EKTAF is priced at $6.06, while LANZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas LANZ's P/E ratio is 2.70. In terms of profitability, EKTAF's ROE is -0.00%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, EKTAF is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check LANZ's competition here
EKTAF vs GMVDF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, GMVDF has a market cap of 52K. Regarding current trading prices, EKTAF is priced at $6.06, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas GMVDF's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, EKTAF is less volatile compared to GMVDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check GMVDF's competition here
EKTAF vs REMI Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, REMI has a market cap of 14K. Regarding current trading prices, EKTAF is priced at $6.06, while REMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas REMI's P/E ratio is -0.07. In terms of profitability, EKTAF's ROE is -0.00%, compared to REMI's ROE of -0.11%. Regarding short-term risk, EKTAF is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check REMI's competition here
EKTAF vs MDIT Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, EKTAF is priced at $6.06, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas MDIT's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, EKTAF and MDIT have similar daily volatility (0.00).Check MDIT's competition here
EKTAF vs ASFX Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ASFX has a market cap of 5.3K. Regarding current trading prices, EKTAF is priced at $6.06, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ASFX's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, EKTAF is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ASFX's competition here
EKTAF vs DGEN Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, EKTAF is priced at $6.06, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas DGEN's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, EKTAF and DGEN have similar daily volatility (0.00).Check DGEN's competition here
EKTAF vs SVSO Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, EKTAF is priced at $6.06, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SVSO's P/E ratio is -0.01. In terms of profitability, EKTAF's ROE is -0.00%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, EKTAF and SVSO have similar daily volatility (0.00).Check SVSO's competition here
EKTAF vs LFPI Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, EKTAF is priced at $6.06, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas LFPI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, EKTAF is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check LFPI's competition here
EKTAF vs SDCCQ Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SDCCQ has a market cap of 1.3K. Regarding current trading prices, EKTAF is priced at $6.06, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, EKTAF is less volatile compared to SDCCQ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SDCCQ's competition here
EKTAF vs INND Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, INND has a market cap of 1.2K. Regarding current trading prices, EKTAF is priced at $6.06, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas INND's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to INND's ROE of -0.01%. Regarding short-term risk, EKTAF and INND have similar daily volatility (0.00).Check INND's competition here
EKTAF vs SEYE Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, EKTAF is priced at $6.06, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SEYE's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to SEYE's ROE of N/A. Regarding short-term risk, EKTAF and SEYE have similar daily volatility (0.00).Check SEYE's competition here
EKTAF vs BGMD Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, EKTAF is priced at $6.06, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas BGMD's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, EKTAF and BGMD have similar daily volatility (0.00).Check BGMD's competition here
EKTAF vs ADLI Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, EKTAF is priced at $6.06, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas ADLI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, EKTAF is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ADLI's competition here
EKTAF vs VSMD Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, VSMD has a market cap of 802. Regarding current trading prices, EKTAF is priced at $6.06, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas VSMD's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, EKTAF is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check VSMD's competition here
EKTAF vs TEVNF Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, EKTAF is priced at $6.06, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas TEVNF's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, EKTAF is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TEVNF's competition here
EKTAF vs HRAL Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, HRAL has a market cap of 396. Regarding current trading prices, EKTAF is priced at $6.06, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas HRAL's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to HRAL's ROE of +0.21%. Regarding short-term risk, EKTAF and HRAL have similar daily volatility (0.00).Check HRAL's competition here
EKTAF vs MICRD Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, EKTAF is priced at $6.06, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas MICRD's P/E ratio is -0.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, EKTAF and MICRD have similar daily volatility (0.00).Check MICRD's competition here
EKTAF vs RGBOQ Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, EKTAF is priced at $6.06, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, EKTAF and RGBOQ have similar daily volatility (0.00).Check RGBOQ's competition here
EKTAF vs SECI Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, SECI has a market cap of 31. Regarding current trading prices, EKTAF is priced at $6.06, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas SECI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to SECI's ROE of -0.00%. Regarding short-term risk, EKTAF and SECI have similar daily volatility (0.00).Check SECI's competition here
EKTAF vs VTEQ Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, EKTAF is priced at $6.06, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to VTEQ's ROE of N/A. Regarding short-term risk, EKTAF and VTEQ have similar daily volatility (0.00).Check VTEQ's competition here
EKTAF vs OCPNY Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, EKTAF is priced at $6.06, while OCPNY trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas OCPNY's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, EKTAF and OCPNY have similar daily volatility (0.00).Check OCPNY's competition here
EKTAF vs MEDVD Comparison May 2026
EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EKTAF stands at 2.2B. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, EKTAF is priced at $6.06, while MEDVD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EKTAF currently has a P/E ratio of -606.00, whereas MEDVD's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MEDVD's ROE of N/A. Regarding short-term risk, EKTAF and MEDVD have similar daily volatility (0.00).Check MEDVD's competition here